Does Botulinum Toxin Type-A Injection an Effective Way of Relieving Pain in Myofascial Pain Syndrome Patients or Not

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-08-26

Study Completion Date

2010-01-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this research prilocaine and botulinum toxin (BoNT-A) interventions prospectively compared to find out the effect of BoNT-A injection on myofascial pain syndrome (MPS).

The main question it aims to answer is: Does Botulinum Toxin Type-A an Effective Way of Relieving Pain in Myofascial Pain Syndrome or not?

For this purpose thirty-eight patients randomly assigned into two study groups. While BoNT-A injection group (BIG group n=19) treated with 20 units of toxin to each trigger point (TP), remaining treated with 2 ml prilocaine (PIG group n=19) with same procedure.

Pre-treatment, 2nd and 6th weeks findings were clinically recorded.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Use of Botulinum Toxin in the Management of Myofascial Pain Syndrome

NCT06824324

Myofacial Pain Syndrome

COMPLETED PHASE1/PHASE2

Acupuncture, Dry Needle and Botox Injection in Management of Patient With Myofascial Pain Dysfunction Syndrome

NCT06013644

Myofascial Trigger Point Pain Myofascial Pain Syndrome

UNKNOWN EARLY_PHASE1

Efficiency of Botulinum Toxin Type-a in the Management of the Myofascial Pain

NCT06840730

Myofascial Pain - Dysfunction Syndrome of TMJ

COMPLETED NA

Botulinum Toxin Type A for Neuroma Pain

NCT01374191

Neuroma

WITHDRAWN PHASE2

A Comparative Study on the Impact of Trigger Points Injection of Platelet Rich Plasma Versus Botulinum Toxin on the Relief of Jaw Muscles Myofascial Pain

NCT06814535

Patients with Jaw Muscles Myofascial Pain

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Visual Analog Scale (VAS), 4-Point Verbal Rating Scale (VRS), Pain Pressure Threshold (PPT), Short Form-36 (SF-36) and Beck Depression Inventory (BDI) tools were used to evaluate findings of the research.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myofacial Pain Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Botulinum toxin injection group (BIG)

Group Type EXPERIMENTAL

Botulinum Toxin A Injection

Intervention Type DRUG

Prilocaine injection group (PIG)

Group Type ACTIVE_COMPARATOR

Prilocaine HCl % 2 injectable solution

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Botulinum Toxin A Injection

Intervention Type DRUG

Prilocaine HCl % 2 injectable solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age ≥ 20 years

Presence of myofascial pain syndrome (MPS) symptoms for more than 3 months

Ability and willingness to provide written informed consent

Exclusion Criteria

Any injection to trigger points within the last 2 months

Diagnosis of fibromyalgia syndrome

Presence of significant respiratory or cardiovascular disease

Presence of psychiatric disorders that may interfere with study participation

History of shoulder or cervical spine intervention within the last year

Presence of cervical myelopathy or cervical radiculopathy

Inability to cooperate with study procedures or assessments

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No